[Tumor lysis syndrome with symptomatic hyperuricemia after a first chemotherapeutic treatment of undifferentiated carcinoma of the cavum].
Penel
N
N
Kouto
H
H
Ala-Eddine
C
C
Degardin
M
M
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D015275:Tumor Lysis Syndrome / Q000175:diagnosis / Q000209:etiology*; D014527:Uric Acid / Q000097:blood*
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001761:Bleomycin; D014527:Uric Acid; D015251:Epirubicin; D002945:Cisplatin
Syndrome de lyse tumorale avec hyperuricémie symptomatique après une première cure de chimiothérapie pour carcinome indifférencié du cavum.